FY2024 EPS Estimates for FibroGen Raised by William Blair

FibroGen, Inc. (NASDAQ:FGEN) – Investment analysts at William Blair upped their FY2024 EPS estimates for FibroGen in a research note issued to investors on Wednesday, November 13th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings per share of ($0.86) for the year, up from their previous estimate of ($1.12). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. William Blair also issued estimates for FibroGen’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.38) EPS.

Separately, StockNews.com started coverage on FibroGen in a research report on Thursday. They set a “hold” rating for the company.

FibroGen Price Performance

Shares of NASDAQ FGEN opened at $0.33 on Monday. The company has a market cap of $33.73 million, a price-to-earnings ratio of -0.27 and a beta of 0.72. The stock’s 50-day moving average is $0.36 and its two-hundred day moving average is $0.71. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the prior year, the company posted ($0.52) EPS.

Institutional Investors Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC lifted its holdings in FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after buying an additional 860,854 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of FibroGen by 139.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of FibroGen in the 3rd quarter valued at $307,000. XTX Topco Ltd acquired a new stake in FibroGen during the 2nd quarter worth $424,000. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares during the last quarter. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.